Category HER2-Negative (HER2-)

CDK4/6 Pathway Dysregulation in Oncology: Molecular Drivers and Targeted Inhibitor Protocols

Mechanism-of-action-of-CDK4-6-inhibitors-Inhibition-of-G1-S-checkpoint | CDK4/6 Pathway

Protocol Summary Receiving an advanced oncology diagnosis necessitates an immediate transition from generalized anatomical staging to precise molecular and genomic profiling. In contemporary clinical oncology, the standard of care dictates that malignancies are evaluated and treated based on their specific,…

AKT Mutation Alterations in Oncology: Molecular Drivers and Targeted Inhibitor Protocols

Schematic-diagram-of-PI3K-Akt-mTOR-pathway-AKT Mutation

Educational Overview Receiving an advanced cancer diagnosis immediately necessitates a transition from generalized anatomical staging to precise molecular profiling. In modern oncology, the standard of care dictates that malignancies are treated based on their specific genetic drivers. Among the most…

Trending now

Storing and Handling Oral Oncology Medications
Storing and Handling Oral Oncology Medications at Home
How Receptor Tyrosine kinase inhibitor works in non-small cell lung cancer
NSCLC Targeted Therapies: Biomarker Profiling and Precision Oncology Protocols
KRAS G12C Mutation involvement in non-small cell lung cancer. The Diagram shows the historical data of this mutation.
KRAS G12C Mutation in Advanced NSCLC: Targeted Therapies and Clinical Management
ROS-1 Gene Fusions in NSCLC: Targeted Therapies and Clinical Management
ROS1 Gene Fusions in NSCLC: Targeted Therapies and Clinical Management